United Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. 

CEO
Martine A. Rothblatt
CEOMartine A. Rothblatt
Employees
1,305
Employees1,305
Headquarters
Silver Spring, Maryland
HeadquartersSilver Spring, Maryland
Founded
1996
Founded1996
Employees
1,305
Employees1,305

UTHR Key Statistics

Market cap
20.02B
Market cap20.02B
Price-Earnings ratio
17.62
Price-Earnings ratio17.62
Dividend yield
Dividend yield
Average volume
376.84K
Average volume376.84K
High today
$470.08
High today$470.08
Low today
$461.45
Low today$461.45
Open price
$468.70
Open price$468.70
Volume
392.43K
Volume392.43K
52 Week high
$519.99
52 Week high$519.99
52 Week low
$266.98
52 Week low$266.98

Stock Snapshot

As of today, United Therapeutics(UTHR) shares are valued at $464.93. The company's market cap stands at 20.02B, with a P/E ratio of 17.62.

On 2026-01-19, United Therapeutics(UTHR) stock moved within a range of $461.45 to $470.08. With shares now at $464.93, the stock is trading +0.8% above its intraday low and -1.1% below the session's peak.

Trading volume for United Therapeutics(UTHR) stock has reached 392.43K, versus its average volume of 376.84K.

Over the past 52 weeks, United Therapeutics(UTHR) stock has traded between a high of $519.99 and a low of $266.98.

Over the past 52 weeks, United Therapeutics(UTHR) stock has traded between a high of $519.99 and a low of $266.98.

UTHR News

Simply Wall St 2d
Assessing United Therapeutics Valuation After Recent Share Price Pullback

Advertisement Recent share performance snapshot Without a specific news catalyst driving trading today, United Therapeutics (UTHR) still gives you a fair bit...

Assessing United Therapeutics Valuation After Recent Share Price Pullback
TipRanks 7d
United Therapeutics’ Phase 3 Ralinepag Trial Reaches Completion, Setting Up a Key Catalyst in Pulmonary Arterial Hypertension

United Therapeutics Corp. (UTHR) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: United Therapeutics is ru...

Analyst ratings

73%

of 15 ratings
Buy
73.3%
Hold
26.7%
Sell
0%

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .